The bean has traveled from soil to cell.
Its resistant carbohydrate has reached the microbiome. Microorganisms have returned part of that carbohydrate as butyrate and acetate. Colonocytes have used butyrate as fuel, and butyrate has influenced gene regulation. Tissues have responded to nutrients, metabolites, structure, and signals.
The biological pathway is now complete.
But a complete pathway is not the same as a health benefit.
To ask whether the journey improves health, we must move through three widening circles of human evidence.
First, intervention trials give people a defined dietary exposure and measure what happens. Second, prospective studies follow large populations whose diets differ. Finally, international disease patterns show how heart disease and colorectal cancer are distributed across regions and nations.
Each circle sees more of human life, but controls less of it.
This is the governing principle of the chapter:
The bean’s biological promise becomes evidence for health only when intervention studies, population studies, and disease patterns point in a consistent direction.
The Bean’s Journey Continues: resistant starch enters a prevention trial
The clearest human experiment begins not with the whole bean but with one feature of its journey: resistant starch.
Resistant starch escapes digestion in the small intestine. In the colon, microorganisms can ferment it and produce short-chain fatty acids, including butyrate. Because butyrate fuels colonocytes and can influence gene regulation, resistant starch became a candidate for colorectal-cancer prevention.
The proposed pathway was compelling:
resistant starch → microbial fermentation → butyrate → altered colonocyte metabolism and regulation → lower cancer risk
Researchers then tested the final arrow in people.
The results show why this final step matters.
Early intervention studies measured changes in the colon
Before a prevention trial can wait for cancer to develop, shorter studies often measure proposed indicators of risk.
In one controlled trial, 23 people who had recently had colorectal adenomas removed received about 28 grams of resistant starch or a digestible-starch comparison for four weeks. Resistant starch changed the bile-acid composition of fecal water but did not change colorectal-cell proliferation, stool weight, fecal pH, or short-chain-fatty-acid excretion.[1]
In another randomized trial, 111 patients with previous sporadic adenomas received calcium, resistant starch, or placebos for two months. Resistant starch did not reduce epithelial-cell proliferation in biopsies taken from several regions of the colorectum.[2]
These findings were mixed rather than simply negative.
The intervention reached the colon and changed part of its chemical environment in one study. The anticipated change in cell proliferation did not appear. More importantly, neither trial measured whether participants later developed colorectal cancer.
Biomarkers can help examine a pathway.
They cannot replace the disease outcome.
CAPP1 tested resistant starch in familial adenomatous polyposis
Familial adenomatous polyposis is an inherited condition in which numerous colorectal adenomas develop, often beginning at a young age. Without appropriate clinical management, colorectal-cancer risk is extremely high.
This made it possible to test prevention over a shorter period than would be practical in the general population.
In the international CAPP1 trial, young people with familial adenomatous polyposis were randomly assigned to resistant starch, aspirin, both, or corresponding placebos. The resistant-starch dose was 30 grams daily.
Resistant starch did not significantly reduce the number or size of colorectal polyps.[3]
Some exploratory measurements in normal-appearing mucosa changed, but the clinical adenoma outcome did not.
The distinction is decisive.
A tissue measurement may suggest that an exposure reached its biological target. If the intended clinical result does not follow, the biomarker cannot be used to declare prevention.
CAPP2 followed resistant starch for as long as twenty years
The most informative resistant-starch experiment involved people with Lynch syndrome.
Lynch syndrome is an inherited disorder of DNA mismatch repair that substantially increases the risk of colorectal cancer and several other cancers. In the CAPP2 trial, participants were randomly assigned in a double-blind design to 30 grams of resistant starch daily or placebo for up to four years. Aspirin was tested independently in the same factorial trial.
The initial results showed no reduction in colorectal adenomas or carcinomas during the intervention period.[4]
The investigators continued to follow participants through cancer registries.
After as long as twenty years, colorectal-cancer incidence still did not differ: 52 participants assigned to resistant starch and 53 assigned to placebo developed colorectal cancer. The estimated hazard ratio was 0.92, with a confidence interval that included both benefit and harm.[5]
For the trial’s central colorectal-cancer question, resistant starch did not demonstrate prevention.
The unexpected CAPP2 finding occurred outside the colorectum
The long follow-up revealed a different result.
Fewer participants assigned to resistant starch developed non-colorectal cancers associated with Lynch syndrome. The reduction was most pronounced for cancers of the upper gastrointestinal tract.[5]
This finding is important and unexpected.
It also requires precise interpretation.
The trial tested a purified resistant-starch preparation, not beans. It enrolled people with Lynch syndrome, not the general population. The effect appeared in non-colorectal Lynch-syndrome cancers, while the predicted colorectal-cancer effect did not appear.
The finding therefore does not establish that beans prevent colorectal cancer.
It suggests that a limited period of resistant-starch exposure may have produced long-lasting effects on selected cancer outcomes in a genetically high-risk population. The mechanism and reproducibility remain subjects for further study.
The Bean’s Journey has taught us to respect the result that occurred—not replace it with the result the pathway predicted.
What the resistant-starch trials say about the bean
Beans naturally contain resistant starch, but the bean and a resistant-starch supplement are not the same intervention.
A whole bean also supplies cell-wall fiber, protein, minerals, folate, and many plant compounds. Its structure controls digestion. Its different substrates support microbial cross-feeding. The amount and type of resistant starch vary with variety, cooking, cooling, and processing.
The trials establish that resistant starch can be consumed in substantial doses for extended periods and can alter some features of the colonic environment. They also show that a plausible butyrate pathway did not translate into fewer colorectal adenomas or colorectal cancers in the high-risk groups studied.
For the whole bean, the conclusion is neither proven nor disproved.
It is more specific:
Resistant starch alone has not demonstrated colorectal-cancer prevention in randomized trials, even though the bean’s wider biological and dietary effects remain relevant to long-term health.
Intervention trials can test years; populations reveal decades
Cancer and heart disease develop over long periods.
Trials that assign people to eat a particular food for decades would be difficult, expensive, and vulnerable to declining adherence. Researchers therefore also study people who have chosen different diets in ordinary life.
A prospective cohort records diet and other characteristics before disease develops, then follows participants for years. Those who consume more fiber can be compared with those who consume less.
These studies cannot control diet as a randomized trial does. People with higher fiber intake may differ in smoking, physical activity, education, body weight, alcohol use, and the rest of their diet. Statistical adjustment can reduce these differences but cannot guarantee their removal.
The advantage is time.
The study can observe heart attacks, strokes, cancers, and deaths rather than only short-term biomarkers.
EPIC followed nearly half a million Europeans
The European Prospective Investigation into Cancer and Nutrition—EPIC—recruited participants through centers in ten European countries. Diets were assessed before disease outcomes occurred, and participants were followed through medical and mortality records.
An analysis of 490,311 adults without prior heart attack or stroke examined plant foods, fiber, and ischemic heart disease over an average of 12.6 years. During follow-up, 8,504 participants developed fatal or nonfatal ischemic heart disease.[6]
Higher total fiber intake was associated with lower risk. For each 10-gram-per-day higher intake, the estimated risk was about 9 percent lower after adjustment for multiple lifestyle and dietary factors.
The association was modest.
It was also broad: total fiber, rather than beans alone, was the exposure that predicted lower risk.
EPIC did not find that legumes alone explained the heart association
The same EPIC analysis examined individual plant-food groups.
Fruit and vegetables combined, nuts and seeds, and total fiber showed inverse associations with ischemic heart disease. Legume intake by itself was not significantly associated with lower risk.[6]
This is an essential finding for a book centered on the bean.
It prevents us from claiming more than the study found.
Beans can contribute to a fiber-rich dietary pattern. They may replace foods with different effects on blood lipids, glucose, energy density, and vascular risk. Yet one food group may be difficult to separate statistically from the larger pattern, especially when intake is low or measured imprecisely.
The European evidence is stronger for fiber-rich plant diets than for beans as an isolated protector against ischemic heart disease.
That does not remove the bean from the story.
It places the bean in the diet where people actually eat it.
European fiber intake was also associated with lower mortality
Another EPIC analysis included 452,717 men and women followed for an average of 12.7 years. During that period, 23,582 deaths occurred.[7]
Each 10-gram-per-day higher fiber intake was associated with about a 10 percent lower overall mortality. Higher fiber was also associated with lower mortality from circulatory and digestive diseases.
Associations were seen particularly for fiber from cereals and vegetables.
Once again, the finding does not identify bean fiber as the sole cause. It shows that higher fiber intake within varied European diets tracked with better long-term outcomes.
The biological route followed in this book makes that association plausible. Fiber changes digestion, fermentation, stool formation, glucose handling, microbial metabolism, and the foods occupying the plate.
Plausibility strengthens an association.
It does not turn observation into randomization.
Fiber connects the bean to heart health by several routes
The heart never encounters an intact bean.
It encounters the consequences of repeated meals.
Bean structure can reduce the rate of glucose delivery. Soluble and viscous components can influence bile-acid handling. Replacing refined starch or foods rich in saturated fat can change the meal’s metabolic composition. Fermentation supplies acetate and other metabolites to circulation. Repeated bean intake has lowered LDL cholesterol in several controlled feeding trials.
These effects converge on cardiovascular risk without requiring one molecule to travel from the bean directly to the coronary artery.
The effects are distributed:
food structure + nutrient replacement + fermentation + repeated metabolic responses → long-term cardiovascular conditions
EPIC observes the outcome of this larger pattern.
It cannot assign a fixed portion of the association to butyrate, acetate, LDL reduction, or any single food.
The world map provides the widest view
International disease statistics reveal striking variation.
Colorectal-cancer incidence differs greatly among regions and countries. According to GLOBOCAN 2022 estimates, colorectal cancer was among the most commonly diagnosed cancers worldwide, but age-standardized incidence rates were much higher in several European, Australasian, and other highly industrialized populations than in many parts of South Asia and Africa.[8]
Ischemic heart disease is even more widespread. The World Health Organization estimated that it caused about nine million deaths in 2021—approximately 13 percent of all deaths globally.[9]
Its burden also varies among countries, reflecting differences in age structure, smoking, blood pressure, cholesterol, diabetes, air pollution, health care, economic conditions, and diet.
These maps show where disease occurs.
They do not show that one food caused the pattern.
National diets change, and disease patterns change with them
Countries do not maintain one traditional diet forever.
Urbanization, income, food processing, refrigeration, transportation, agricultural policy, and global trade change what people eat. Traditional meals built around grains, beans, vegetables, and modest amounts of animal food may give way to diets containing more refined starch, processed meat, added fat, sugar-sweetened drinks, and highly processed snacks.
At the same time, people may become less physically active, live longer, gain access to screening, and receive better treatment for infection and acute disease. Cancer registries and death certification also improve.
When colorectal cancer or heart disease rises during this transition, diet is one plausible contributor among many.
Japan and South Korea provide important examples. In Japan, meat, dairy, egg, and fat consumption rose markedly from about 1950 to 1970. Roughly two decades later, colon-cancer incidence increased substantially; compared with 1975, age-adjusted rates by 1995–2000 were estimated to be 3.7 times higher in men and 2.9 times higher in women.[10,11] South Korea underwent a later transition. Between 1999 and 2009, age-standardized colorectal-cancer incidence rose from 27.0 to 50.2 per 100,000 men and from 17.2 to 26.9 per 100,000 women, with the fastest increase occurring in the distal colon.[12]
These parallel changes are consistent with a contribution from changing diet and lifestyle, but they do not establish that dietary Westernization—or the loss of beans or fiber—caused the increase. Aging, obesity, physical inactivity, alcohol, smoking, screening, and improved cancer registration changed during the same period.
The comparison cannot tell us how much of the change was caused by lower bean intake or lower fiber alone.
The ecological pattern is a signal.
It is not a controlled experiment.
High incidence can reflect both greater risk and greater detection
A country with extensive colorectal screening may identify cancers that would have remained undiagnosed elsewhere. A country with strong medical records will count cases more completely. An older population will experience more cancer and heart disease than a younger one even if individual risk is similar.
Age-standardized rates help compare populations with different age structures, but they cannot equalize screening, registry quality, treatment access, or competing causes of death.
Mortality adds another layer.
A high incidence with lower mortality may reflect early detection and effective treatment. A lower recorded incidence with high case fatality may reflect delayed diagnosis or incomplete registration.
Global differences are real.
Their interpretation requires humility.
The bean is most visible within traditional food systems
Across Latin America, the Caribbean, Africa, the Mediterranean region, South Asia, and other parts of the world, pulses have long been paired with staple grains or roots.
These meals did more than combine nutrients.
They organized the diet around foods that provided fiber, slowly available carbohydrate, plant protein, minerals, and fermentable substrate. Beans often displaced a portion of more expensive animal food and made staple-based meals nutritionally stronger.
The health effect cannot be assigned to the bean alone. Vegetables, fruits, whole grains, physical activity, smoking, alcohol, salt, cooking fats, infection, medical care, and social conditions shape the same populations.
But removing beans from a traditional meal changes more than one ingredient.
It changes the structure of the food system.
Three circles of evidence now surround the bean
The human evidence can be seen as three concentric circles.
The intervention circle
Researchers assign an exposure and measure the result. Resistant-starch trials show that biologically active colonic exposure does not guarantee colorectal-cancer prevention. Controlled bean trials show changes in selected risk factors such as post-meal glucose and LDL cholesterol.
The cohort circle
Researchers follow people for years. European studies associate higher total fiber intake with lower ischemic-heart-disease risk and mortality, while the evidence for legumes alone is less distinct.
The global circle
Registries show enormous international variation in colorectal cancer and heart disease. These patterns are compatible with major roles for diet and lifestyle but cannot isolate the bean from the many forces that differ among nations.
No circle is sufficient by itself.
Together they create a more complete judgment.
What the evidence supports
The evidence supports several conclusions.
Beans deliver fermentable carbohydrate through a whole-food structure. Their resistant starch and fiber enter pathways that are relevant to colon function and systemic metabolism. Controlled feeding trials show that beans can improve selected physiological risk factors under defined conditions. Large European cohorts associate higher fiber intake with lower ischemic-heart-disease risk and lower mortality. International patterns show that heart disease and colorectal cancer are strongly shaped by environments and ways of living.
The evidence does not support several stronger conclusions.
Purified resistant starch has not reduced colorectal-cancer incidence in randomized trials, even among genetically high-risk participants. EPIC did not show that legume intake alone explained lower ischemic-heart-disease risk. International differences cannot prove that countries with more beans have less disease because of beans.
The bean contributes to a protective dietary environment.
It does not determine the outcome alone.
The Bean’s Journey: biology meets human history
The journey began inside one seed.
It now extends across decades and populations.
In an intervention trial, resistant starch reaches the colon but does not necessarily prevent colorectal cancer. In a cohort, fiber-rich diets are associated with lower cardiovascular risk over years. On the world map, disease follows broad patterns of diet, development, aging, behavior, screening, and health care.
The bean remains present at every scale.
It carries resistant carbohydrate to the microbiome. It contributes fiber to the diet. It can replace more rapidly digested or less fiber-rich food. Repeated across a lifetime, it becomes part of a dietary pattern.
The meaning of the bean grows with the system around it.
The Bean at This Stage
The bean has reached the final level of the Evidence Pathway.
Its contents are known. Its digestion and fermentation have been traced. Its metabolites have been measured. Its cellular and tissue effects are biologically credible. Human interventions show selected physiological effects, while resistant-starch prevention trials show the limits of mechanism. Prospective studies support fiber-rich diets, and global disease patterns show the scale on which diet acts alongside many other forces.
The result is not a miracle claim.
It is a disciplined conclusion:
Beans can contribute meaningfully to a fiber-rich dietary pattern that supports long-term health, but no single bean, nutrient, or microbial metabolite guarantees protection from disease.
Next — The Long View: The Bean at the Table
The evidence has followed the bean into people and populations.
The next chapter returns it to the table.
It asks how repeated bean-containing meals fit within traditional and modern diets, what foods they replace, how they can be prepared and tolerated, and what role they can reasonably play across a lifetime.
Notes and selected references
- Grubben MJ, van den Braak CC, Essenberg M, et al. Effect of resistant starch on potential biomarkers for colonic cancer risk in patients with colonic adenomas: a controlled trial. Digestive Diseases and Sciences. 2001;46(4):750–756. doi:10.1023/A:1010787931002.
- van Gorkom BAP, Karrenbeld A, van der Sluis T, et al. Calcium or resistant starch does not affect colonic epithelial cell proliferation throughout the colon in adenoma patients: a randomized controlled trial. Nutrition and Cancer. 2002;43(1):31–38. doi:10.1207/S15327914NC431_3.
- Burn J, Bishop DT, Chapman PD, et al. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prevention Research. 2011;4(5):655–665. doi:10.1158/1940-6207.CAPR-11-0106.
- Burn J, Bishop DT, Mecklin JP, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. New England Journal of Medicine. 2008;359(24):2567–2578. doi:10.1056/NEJMoa0801297.
- Mathers JC, Elliott F, Macrae F, et al. Cancer prevention with resistant starch in Lynch syndrome patients in the CAPP2 randomized placebo-controlled trial: planned 10-year follow-up. Cancer Prevention Research. 2022;15(9):623–634. doi:10.1158/1940-6207.CAPR-22-0044.
- Perez-Cornago A, Crowe FL, Appleby PN, et al. Plant foods, dietary fibre and risk of ischaemic heart disease in the European Prospective Investigation into Cancer and Nutrition cohort. International Journal of Epidemiology. 2021;50(1):212–222. doi:10.1093/ije/dyaa155.
- Chuang SC, Norat T, Murphy N, et al. Fiber intake and total and cause-specific mortality in the European Prospective Investigation into Cancer and Nutrition cohort. American Journal of Clinical Nutrition. 2012;96(1):164–174. doi:10.3945/ajcn.111.028415.
- International Agency for Research on Cancer. Global Cancer Observatory: GLOBOCAN 2022—Colorectum fact sheet. Lyon: IARC; 2024.
- World Health Organization. Global Health Estimates 2021: deaths by cause, age, sex, by country and by region, 2000–2021. Geneva: WHO; 2024.
- Kono S. Secular trend of colon cancer incidence and mortality in relation to fat and meat intake in Japan. European Journal of Cancer Prevention. 2004;13(2):127–132. doi:10.1097/00008469-200404000-00006.
- Kuriki K, Tajima K. The increasing incidence of colorectal cancer and the preventive strategy in Japan. Asian Pacific Journal of Cancer Prevention. 2006;7(3):495–501.
- Shin A, Kim KZ, Jung KW, et al. Increasing trend of colorectal cancer incidence in Korea, 1999–2009. Cancer Research and Treatment. 2012;44(4):219–226. doi:10.4143/crt.2012.44.4.219.